95 related articles for article (PubMed ID: 17823530)
1. Exfoliative eruption secondary to gefitinib (ZD1839).
Becuwe C; Dalle S; Arpin D; Balme B; Thomas L
Dermatology; 2007; 215(3):266-8. PubMed ID: 17823530
[No Abstract] [Full Text] [Related]
2. Severe cutaneous toxicity following treatment with gefitinib (ZD1839).
Pascual JC; Belinchón I; Sivera F; Yuste A
Br J Dermatol; 2005 Dec; 153(6):1222-3. PubMed ID: 16307664
[No Abstract] [Full Text] [Related]
3. Acneiform lesions secondary to ZD1839, an inhibitor of the epidermal growth factor receptor.
Fernandez-Galar M; España A; López-Picazo JM
Clin Exp Dermatol; 2004 Mar; 29(2):138-40. PubMed ID: 14987267
[TBL] [Abstract][Full Text] [Related]
4. Severe purpuric xerotic dermatitis associated with gefitinib therapy.
Sheen YS; Hsiao CH; Chu CY
Arch Dermatol; 2008 Feb; 144(2):269-70. PubMed ID: 18283195
[No Abstract] [Full Text] [Related]
5. Gefitinib-induced acute generalized exanthematous pustulosis in two patients with advanced non-small-cell lung cancer.
Shih HC; Hsiao YP; Wu MF; Yang JH
Br J Dermatol; 2006 Nov; 155(5):1101-2. PubMed ID: 17034565
[No Abstract] [Full Text] [Related]
6. Rare cutaneous side-effect of gefitinib masquerading as superficial dermatophytosis.
Lin SS; Tsai TH; Yang HH
Clin Exp Dermatol; 2009 Jun; 34(4):528-30. PubMed ID: 19196304
[No Abstract] [Full Text] [Related]
7. Trichomegaly following treatment with gefitinib (ZD1839).
Pascual JC; Bañuls J; Belinchon I; Blanes M; Massuti B
Br J Dermatol; 2004 Nov; 151(5):1111-2. PubMed ID: 15541102
[No Abstract] [Full Text] [Related]
8. Erlotinib-associated dermatological toxicity.
Mumoli N; Cei M; Vitale J
QJM; 2013 Apr; 106(4):363-4. PubMed ID: 22927541
[No Abstract] [Full Text] [Related]
9. Epidermal growth factor receptor (EGFR) inhibitor associated skin eruption.
Seiverling EV; Fernanadez EM; Adams D
J Drugs Dermatol; 2006 Apr; 5(4):368-9. PubMed ID: 16673807
[TBL] [Abstract][Full Text] [Related]
10. Erlotinib-induced skin manifestations.
Motoki T; Mitsuishi T; Kawana S
J Dermatol; 2009 Dec; 36(12):658-9. PubMed ID: 19958452
[No Abstract] [Full Text] [Related]
11. Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor.
Van Doorn R; Kirtschig G; Scheffer E; Stoof TJ; Giaccone G
Br J Dermatol; 2002 Sep; 147(3):598-601. PubMed ID: 12207609
[TBL] [Abstract][Full Text] [Related]
12. Stevens-Johnson syndrome-like erosive dermatitis possibly related to afatinib.
Honda Y; Hattori Y; Katsura S; Terashima T; Manabe T; Otsuka A; Miyachi Y
Eur J Dermatol; 2016 Aug; 26(4):413-4. PubMed ID: 27212422
[No Abstract] [Full Text] [Related]
13. Severe acneiform skin reaction during therapy with erlotinib (Tarceva), an epidermal growth factor receptor (EGFR) inhibitor.
Eames T; Landthaler M; Karrer S
Eur J Dermatol; 2007; 17(6):552-3. PubMed ID: 17951151
[No Abstract] [Full Text] [Related]
14. A man whose scapula was spared a drug-associated rash.
Sanz A; del Valle ML
CMAJ; 2005 Mar; 172(6):745. PubMed ID: 15767607
[No Abstract] [Full Text] [Related]
15. Purpuric drug eruption possibly due to gefinitib (Iressa).
Kurokawa I; Endo K; Hirabayashi M
Int J Dermatol; 2005 Feb; 44(2):167-8. PubMed ID: 15689221
[No Abstract] [Full Text] [Related]
16. Acneiform eruption induced by Iressa (gefitinib) tablets used to treat non-small cell lung cancer.
Warthan MM; Jumper CA; Smith JL
J Drugs Dermatol; 2004; 3(5):569-70. PubMed ID: 15552613
[TBL] [Abstract][Full Text] [Related]
17. Livedo reticularis with retiform purpura associated with gefitinib (Iressa).
Blume JE; Miller CC
Int J Dermatol; 2007 Dec; 46(12):1307-8. PubMed ID: 18173531
[No Abstract] [Full Text] [Related]
18. Follicular drug eruption induced by gefitinib (ZD 1839, iressa): clinical picture correlates with in vitro data of focal epidermal necrosis after epidermal growth factor inhibition in skin cultures.
Treudler R; Zouboulis CC
Dermatology; 2005; 211(4):375-6. PubMed ID: 16286753
[No Abstract] [Full Text] [Related]
19. Skin rash as a surrogate marker of clinical response of targeted therapy using gefitinib in advanced or metastatic non-small-cell lung cancer--a retrospective study.
Acharyya S; Sau S; Dasgupta P; Chakraborty A; Gangopadhyay S
J Indian Med Assoc; 2012 Jul; 110(7):474-6, 493. PubMed ID: 23520673
[TBL] [Abstract][Full Text] [Related]
20. Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib.
Graves JE; Jones BF; Lind AC; Heffernan MP
J Am Acad Dermatol; 2006 Aug; 55(2):349-53. PubMed ID: 16844529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
